![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NeoGenomics Snags GE Healthcare Unit Clarient
NeoGenomics Snags GE Healthcare Unit Clarient
January 4, 2016
NeoGenomics has completed its acquisition of cancer diagnostic testing provider Clarient for a $80 million in cash, $110 million in preferred stock and 15 million shares of NeoGenomics common stock.
A unit of GE Healthcare, Clarient’s portfolio includes diagnostics for a variety of fields, including breast and colorectal cancer testing, as well as leukemia and lymphoma testing. As a result, GE will own about 32 percent of NeoGenomics. — Michael Cipriano
Upcoming Events
-
21Oct